Biologics, SCOTUS' take on patent settlements boost Big Pharma

03/28/2013 | Forbes

Supreme Court justices expressed skepticism that patent settlements between brand-name and generic-drug makers should be unilaterally declared anti-competitive, writes Bruce Japsen. Generic drugs have cut into profits as Big Pharma has struggled to fill pipelines, and the news boosted stock values. Big Pharma is increasingly focused on developing complex biologic drugs to treat diseases such as cancer, multiple sclerosis and autoimmune disorders.

View Full Article in:

Forbes

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN